This article provides an overview of the medication issues and concerns that social workers may
encounter when participating in the treatment of clients who suffer from major depression. This
overview includes information about the condition of major depression, the medications used to
treat this disorder, their short- and long-term efficacy, side effects, and other important
considerations for effective social work.
Get full access to this article
View all access options for this article.
References
1.
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author .
2.
Austrian, S.G. (1995). Mental disorders, medications and clinical social workNew York: Columbia University Press.
3.
Beck, A.T. (1967). Depression: Clinical, experimental and theoretical aspects. New York: Harper & Row.
4.
Bentley, K.J., (1997). Should clinical social workers seek psychotropic medication prescnption privileges ? : No. In B. A. Thyer (Ed.), Controversial issues in social work practice . (pp. 152-165). Boston: Allen & Bacon.
5.
Bentley, K.J., & Walsh, J. (1996). The social worker and psychotropic medication: Toward effective collaboration with mental health clients, families, and providersPacific Grove, CA: Brooks/Cole .
6.
Brophy, J.J. (1991). Psychiatric Disorders. In S A. Schroeder, M. A. Krupp, L. M. Tierney, & S J. McPhee (Eds ), Current medical diagnosis & treatment (30th ed., pp 731-786). Norwalk, CT : Appleton & Lange.
7.
Cowley, G. (1994, February 7) The culture of prozac. Newsweek, 41-42.
8.
Craig, C. (1995). Teaching food-drug interactions. Journal of Psychological Nursing, 33, 44-46.
9.
de Vane, C.L. (1994) Pharmacogenetics and drug metabolism of the newer antidepressant agents. Journal of Clinical Psychiatry, 55(12), 38-45.
10.
Dziegielewski, S.F. (1996). Managed care principles: The need for social work in the health care environment. Crisis Intervention, 3, 97-111.
11.
Dziegielewski, S.F. (1997). Should clinical social workers seek psychotropic medication prescription privileges?: Yes. In B. A. Thyer (Ed.), Controversial issues in social work practice (pp. 152-165). Boston: Allyn & Bacon.
12.
Dziegielewski, S.F. (1998) The changing face of health care social work: An empirical approach to practiceNew York: Springer.
13.
Gitlin, M.J. (1996) The psychotherapist's guide to psychopharmacology (2nd ed.). New York: Free Press.
14.
Hamilton, M.S., & Opler, L.A. (1992). Akathisia, suicidality, and fluoxetine. Journal of Clinical Psychiatry, 53, 401-406.
15.
Higgins, E. (1994) Areview of unrecognized mental illness in primary care: Prevalence, natural history, and efforts to change the course. Archives of Family Medicine, 3, 899-907.
16.
Hook, M.P. (1996) Challenges to identifying and treating women with depression in rural primary care. Social Work in Health Care , 23(3), 73-92.
Jann, M.W., Jemke, M.A., & Lieberman, J.A. (1994). The new psychopharmaceuticals . Patient Care, 28(2), 47-49.
19.
Kaplan, H.I., & Sadock, B.J. (1990). Pocket handbook of clinical psychiatry. Baltimore, MD: Williams & Wilkins.
20.
Kellner, R. (1986) The Brief Depression Rating Scale. In N. Sartonus & T. A. Ban (Eds.), Assessment of depression (pp. 179-183). New York: Springer-Verlag.
21.
Larkin, M. (1993, March). Types of antidepressants. FDA Consumer, pp. 21-22.
22.
Lehne, R.A., & Scott, D. (1996). Psychopharmacology. In V B. Carson & E. N. Arnold (Eds.), Mental health nursing: The nurse patient journey (pp. 523-570). Philadelphia: W.B. Saunders.
23.
Lemonick, M.D. (1997, September 29). The mood molecule. Time, 74-82.
24.
Mann, J.J., & Kapur, S. (1991). The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy. Archives of General Psychiatry, 48, 1027-1033.
25.
Merck Research Laboratories. (1992). The Merck manual of diagnosis and therapy (16th ed.). Rahway, NJ. Author.
26.
Physicians' Desk Reference. (1997a) Physicians' desk reference (51st ed.). Montvale, NJ. Medical Economics Company.
27.
Physicians' Desk Reference (1997b) Physicians' desk reference: For nonprescnption drugs (18th ed ) Montvale, NJMedical Economics Company .
28.
Radloff, L.S. (1977) The CES-D scale: A self-report depression scale for research in the general population. Applied Psychological Measurement, 1, 385-401.
29.
Resmck, W.M. , & Carson, V.B. (1996) The Journey colored by mood disorders In V B. Carson & E N Arnold (Eds.), Mental health nursing: The nurse patient journey (pp. 759-792) Philadelphia. W B. Saunders.
30.
Rush, J. (1993, June) Depression in primary care: Detection, diagnosis and treatment. American Family Physician, 47, 1766-1788.
31.
Schatzberg, A.F., & Cole, J.O. (1991) Manual of clinical psychopharmacology (2nd ed.). Washington, DC. American Psychiatric Press.
32.
Teicher, M.H. , Glod, C., & Cole, J.O. (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. American Journal of Psychiatry, 147, 207-210.
33.
Tierney, L. M., McPhee, S. J., & Papadakis, M. A. (Eds.). (1997). Current medical diagnosis and treatment (36th ed.). Stamford, CT: Appleton & Lange.
34.
Tollefson, G.D., Ramphey, A.H., Beasley, C.M., Enas, C.G., & Potvin, J.H. (1994). Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. Journal of Clinical Psychopharmacology, 14, 163-169.
35.
World Health Organization. (1992). International classification of diseases (10th ed.). Geneva: Author.
